Age, years (± SD)
|
69.18 (± 12.19)
|
70.15 (± 13.35)
|
0.610
|
70.15 (± 14.25)
|
67.98 (± 14.88)
|
0.254
|
Sex (M)
|
29 (52.7%)
|
222 (54.0%)
|
0.886
|
26 (39.4%)
|
346 (47.0%)
|
0.235
|
Body weight (kg)
|
Comorbidity
|
DM
|
19 (34.5%)
|
121 (29.4%)
|
0.531
|
25 (37.9%)
|
238 (32.3%)
|
0.358
|
Liver cirrhosis
|
6 (10.9%)
|
31 (7.5%)
|
0.422
|
4 (6.1%)
|
54 (7.3%)
|
1.000
|
ESRD on HD
|
4 (7.3%)
|
7 (1.7%)
|
0.031*
|
6 (9.1%)
|
18 (2.4%)
|
0.010*
|
ESRD on PD
|
0 (0.0%)
|
0 (0.0%)
|
N.A.
|
2 (3.0%)
|
4 (.0.5%)
|
0.081
|
Rheumatic disease
|
1 (1.8%)
|
0 (0.0%)
|
0.119
|
2 (3.0%)
|
15 (2.0%)
|
0.644
|
Haematologic malignancy
|
4 (7.3%)
|
8 (2.0%)
|
0.042*
|
12 (18.2%)
|
109 (14.9%)
|
0.474
|
Solid malignancy
|
17 (30.9%)
|
149 (36.4%)
|
0.457
|
16 (24.2%)
|
176 (24.0%)
|
0.966
|
Solid organ transplantation
|
2 (3.6%)
|
9 (2.2%)
|
0.627
|
4 (6.1%)
|
19 (2.6%)
|
0.113
|
Bone marrow transplantation
|
2 (3.6%)
|
1 (0.2%)
|
0.038*
|
2 (3.0%)
|
22 (3.0%)
|
1.000
|
Intravascular device
|
75 (18.2%)
|
26 (47.3%)
|
0.000*
|
4 (6.1%)
|
19 (2.6%)
|
0.113
|
Neutropenia
|
1 (1.8%)
|
8 (2.0%)
|
1.000
|
11 (16.7%)
|
105 (14.3%)
|
0.608
|
High-dose steroid
|
1 (1.8%)
|
4 (1.0%)
|
0.468
|
4 (6.1%)
|
15 (2.0%)
|
0.063
|
Microorganism
|
Escherichia coli
|
22 (40.0%)
|
205 (49.9%)
|
0.197
|
36 (54.5%)
|
456 (62.0%)
|
0.291
|
Klebsiella pneumoniae
|
11 (20.0%)
|
91 (22.1%)
|
0.735
|
14 (21.2%)
|
133 (18.1%)
|
0.527
|
Pseudomonas aeruginosa
|
5 (9.1%)
|
19 (4.6%)
|
0.185
|
5 (7.6%)
|
33 (4.5%)
|
0.231
|
vAmpC-encoded Enterobacteriaceaea
|
7 (12.7%)
|
49 (11.9%)
|
1.000
|
4 (6.1%)
|
39 (5.3%)
|
0.774
|
Acinetobacter baumannii
|
1 (1.8%)
|
6 (1.5%)
|
0.587
|
2 (3.0%)
|
15 (2.0%)
|
0.644
|
ESBL-producing
|
21 (38.2%)
|
84 (20.4%)
|
0.003*
|
39 (59.1%)
|
169 (23.0%)
|
0.000*
|
Other gram-negative
|
9 (16.4%)
|
34 (8.3%)
|
0.052*
|
5 (7.6%)
|
59 (8.0%)
|
0.899
|
PBSI
|
5 (9.1%)
|
32 (7.8%)
|
0.789
|
1 (1.5%)
|
12 (1.6%)
|
1.000
|
Hospital onset
|
22 (40.0%)
|
66 (16.1%)
|
0.000*
|
19 (28.8%)
|
216 (29.3%)
|
1.000
|
Site of infection
|
Urinary genital tract
|
12 (21.8%)
|
80 (19.5%)
|
0.718
|
38 (57.6%)
|
372 (50.5%)
|
0.305
|
Liver abscess
|
2 (3.6%)
|
39 (9.5%)
|
0.205
|
0 (0.0%)
|
13 (1.8%)
|
0.615
|
Biliary infection
|
9 (16.4%)
|
218 (53.0%)
|
0.000*
|
1 (1.5%)
|
73 (9.9%)
|
0.024*
|
Intra-abdominal
|
5 (9.1%)
|
38 (9.2%)
|
1.000
|
6 (9.1%)
|
85 (11.5%)
|
0.687
|
Respiratory
|
1 (1.8%)
|
2 (0.5%)
|
0.315
|
7 (10.6%)
|
44 (6.0%)
|
0.180
|
SSTI
|
3 (5.5%)
|
4 (1.0%)
|
0.039*
|
2 (3.0%)
|
4 (0.5%)
|
0.081
|
Catheter-related
|
18 (32.1%)
|
22 (5.4%)
|
0.000*
|
0 (0.0%)
|
0 (0.0%)
|
N.A.
|
Bone and joint infection
|
3 (5.5%)
|
2 (0.5%)
|
0.013*
|
1 (1.5%)
|
6 (0.8%)
|
0.453
|
Cardiovascular
|
2 (3.6%)
|
1 (0.2%)
|
0.038*
|
0 (0.0%)
|
0 (0.0%)
|
N.A.
|
CNS infection
|
0 (0.0%)
|
0 (0.0%)
|
N.A.
|
0 (0.0%)
|
2 (0.2%)
|
1.000
|
Primary bacteraemia
|
0 (0.0%)
|
0 (0.0%)
|
N.A.
|
11 (16.7%)
|
131 (17.8%)
|
0.869
|
Inotropic requirement on the day of FUBC
|
24 (5.8%)
|
10 (18.2%)
|
0.003*
|
9 (13.6%)
|
53 (7.2%)
|
0.061
|
Unfavourable treatment response
|
30 (55.6%)
|
130 (32.5%)
|
0.001*
|
31 (48.4%)
|
215 (30.0%)
|
0.002*
|
qSOFA score (± SD) on the day of FUBC
|
1.29 (± 1.12)
|
0.52 (± 0.76)
|
0.000*
|
0.88 (± 0.95)
|
0.56 (± 0.88)
|
0.005*
|
SOFA score (± SD) on the day of FUBC
|
5.62 (± 4.48)
|
3.09 (± 2.93)
|
0.000*
|
3.79 (± 3.47)
|
2.90 (± 3.18)
|
0.036*
|
qSOFA score ≥ 2 on the day of FUBC
|
20 (36.4%)
|
45 (10.9%)
|
0.000*
|
16 (24.2%)
|
108 (14.7%)
|
0.039
|
Effective antibiotics before the day of FUBC
|
34 (61.8%)
|
350 (85.2%)
|
0.000*
|
27 (40.9%)
|
639 (86.8%)
|
0.000*
|
Adequate source control before the day of FUBC
|
13 (23.6%)
|
322 (78.3%)
|
0.000*
|
N.A.
|
N.A.
|
N.A.
|